Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low - Should You Sell?

Key Points

• Amphastar Pharmaceuticals shares have hit a new 52-week low, trading down to $20.40, with a last trading price of $21.02.
• Analysts predominantly maintain a "hold" rating on the stock, with the consensus price target set at $32.33 after several revisions from major firms.
• Recent activity from institutional investors shows significant inflows, with some firms increasing their stakes by over 192% in recent quarters.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report)'s share price reached a new 52-week low on Friday . The stock traded as low as $20.40 and last traded at $21.02, with a volume of 2232 shares changing hands. The stock had previously closed at $20.95.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Wells Fargo & Company cut their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Stock Up 1.2%

The firm has a fifty day simple moving average of $23.71 and a 200 day simple moving average of $26.69. The company has a market cap of $999.84 million, a PE ratio of 7.68 and a beta of 0.76. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.02 and a current ratio of 2.95.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AMPH. Tower Research Capital LLC TRC increased its holdings in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares in the last quarter. Huntington National Bank grew its stake in shares of Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after buying an additional 361 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Amphastar Pharmaceuticals by 4.6% during the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after buying an additional 361 shares during the period. GAMMA Investing LLC raised its holdings in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after buying an additional 424 shares during the period. Finally, Hohimer Wealth Management LLC lifted its position in Amphastar Pharmaceuticals by 6.9% during the 1st quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company's stock worth $232,000 after acquiring an additional 520 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.